Phase 3 Clinical Trials With Primary Completion Dates in July 2019
This is a list of Phase 3 trials with primary completion dates in July 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALKS | Alkermes plc | 2019-07-01 | Phase 3 | NCT03093324 | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 |
| ALNA | Allena Pharmaceuticals, Inc. | 2019-07-01 | Phase 3 | NCT03456830 | Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria |
| MNK | Mallinckrodt plc | 2019-07-01 | Phase 3 | NCT03005106 | StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements |
| NVCR | NovoCure Limited | 2019-07-01 | Phase 3 | NCT02831959 | Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS) |
| OBSV | ObsEva SA | 2019-07-01 | Phase 3 | NCT03070899 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids |
| RTTR | Ritter Pharmaceuticals, Inc. | 2019-07-01 | Phase 3 | NCT03597516 | Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance |
| SNY | Sanofi | 2019-07-01 | Phase 3 | NCT02993757 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® |
| ZEAL | Zealand Pharma A/S | 2019-07-01 | Phase 3 | NCT03667053 | Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children |